Abstract:Purpose/Objective(s) programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still unsatisfactory. Basic studies have already confirmed PD-1 inhibitors had concurrent synergistic effect with chemotherapy and radiotherapy. Few studies concerned about the treatment pattern for concurrent PD-1 inhibitors combination with chemoradiation for R/M NPC. There was still much uncertainty about the timing, fraction dose and total dose for PD-1 inhibitors combination with radiation. Therefore, we aimed to explore the substantial effect and toxicity of this new pattern for R/M NPC. Materials/Methods We prospectively enrolled 42 R/M NPC patients from August 2018 to May 2021 in out institution. All the patients received concurrent PD-1 inhibitor combination with chemoradiation, and followed with maintenance of PD-1 inhibitors, and we analyzed PD-L1 expression by 22C3 kit. Objective response rate (ORR) and disease control rate (DCR) were calculated by irRECIST 1.1. CTCAE-5.0 was used to evaluate the toxicity and Kaplan-Meier method was used to analyze survival rate. Results The median age was 48 years old (range 25-81), the median follow up time was 16.5 months (range 2-62). Nine patients had recurrent disease, 33 patients had metastatic disease, and 3 patients had both recurrence and metastasis disease. The median numbers of metastatic sites were 3 (range 1-7), and the most common metastatic sites were lung and liver. All the recurrent and measurable metastatic lesions were treated with radiotherapy. 9 recurrent patients received a median radiation dose of 60Gy. The measurable metastatic lesions received a median radiation dose of 54Gy. The median cycles of cisplatin-based chemotherapy were 5. Median time of PD-1 inhibitor was 9.5 months. At 3 months after the completion of chemoradiation, ORR and DCR were 90.5% and 100% respectively. The median PFS was 18 months, with 6 and 12 months PFS rates were 90.2% and 70.7%. 1 and 2-years OS rates were 94.6% and 86.2%, and the median OS had not reached. For the PD-L1 expression, 24 patients were positive, 18 were negative. The median PFS was 20.7 and 16.5 months for positive and negative group, respectively (p=0.01). Most common G3-4 toxicities were leucopenia (45.2%), anemia (38.1%), anorexia (7.1%), and fatigue (7.1%). There was no G3-4 toxicity for pneumonia, and no G5 toxicity was observed. Conclusion This new treatment pattern of concurrent PD-1 inhibitors combination with chemoradiation shows a promising efficacy and tolerable toxicity for R/M NPC. The patients with positive PD-L1 expression had better survival outcome than negative group. Keywords: PD-1 inhibitors, concurrent, recurrent, metastatic, nasopharyngeal carcinoma, chemoradiation

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

Preliminary Analysis of Concurrent Programmed Cell Death-1 Inhibitor Combination with Chemoradiation for Recurrent/Metastatic Nasopharyngeal Carcinoma Patients: A Phase II Study

Anti-PD-(L)1-Based Neoadjuvant Therapy in Head and Neck Carcinoma: a Meta-analysis of Prospective Clinical Trials.

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer

Combination of Radiosensitivity Gene Signature and PD-L1 Status Predicts Clinical Outcome of Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Study Based on the Cancer Genome Atlas Dataset

An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC

The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell carcinoma

Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC

Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.

A prospective, single-arm trial of PD-1 inhibitors plus chemoradiotherapy for solitary metachronous metastasis nasopharyngeal carcinoma

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma

First‐line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A retrospective cohort study

Neoadjuvant Chemoimmunotherapy Shows Major Pathological Response and Low Recurrence in Head and Neck Squamous Cell Carcinoma

Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review

P83.04 Efficacy and Safety of Combining Programmed Cell Death-1 Inhibitor and Anti-Angiogenic Agent As Subsequent Therapy for Advanced NSCLC

Programmed Cell Death 1 Inhibitors with or Without Concurrent Brain Radiotherapy for Lung Cancer Patients with Brain Metastases

Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis

PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers

Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study